Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer

Sponsor
South Eastern European Research Oncology Group
Study ID
NCT01195298
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
70 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Capecitabine and Bevacizumab — DRUG
    Drugs will be administered in 3-week cycles as follows: * Bevacizumab 15mg/kg via i.v. infusion on day 1 * Capecitabine 1000 mg/m2 tablets twice-daily, on days 1 through 14.

Study Details

This is an open-label, single-arm, multicenter study of capecitabine and bevacizumab administered as first-line treatment of previously untreated elderly patients, older than 70 years, with metastatic or locally recurrent breast cancer.

Key Dates

First listed
Sep 6, 2010
Start date
May 31, 2010
Status verified
Aug 2010
Primary completion
Aug 31, 2011

Study Design

Enrollment
88 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Time to treatment progression [ Time Frame: average 5 years ]

Related Studies